Zobrazeno 1 - 10
of 232
pro vyhledávání: '"M. Van Den Eynde"'
Autor:
C. van Marcke, N. Honoré, A. van der Elst, S. Beyaert, F. Derouane, C. Dumont, F. Aboubakar Nana, J. F. Baurain, I. Borbath, P. Collard, F. Cornélis, A. De Cuyper, F. P. Duhoux, B. Filleul, R. Galot, M. Gizzi, F. Mazzeo, T. Pieters, E. Seront, I. Sinapi, M. Van den Eynde, N. Whenham, J. C. Yombi, A. Scohy, A. van Maanen, J. P. Machiels
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. The safety of systemic anti-can
Externí odkaz:
https://doaj.org/article/95bcb44e832f4789979432b41c90aaa4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Emmanuel Seront, M. Van den Eynde, Thierry Pieters, Anaïs Scohy, Philippe Collard, C. Dumont, F. Aboubakar Nana, A. van der Elst, R. Galot, Jean Cyr Yombi, Frank Cornelis, Simon Beyaert, Marco Gizzi, Ivan Borbath, F. Derouane, A. van Maanen, Filomena Mazzeo, N. Whenham, N. Honoré, François Duhoux, A. De Cuyper, Jean-François Baurain, Bertrand Filleul, I. Sinapi, J.-P. Machiels, C. van Marcke
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer
BMC cancer, Vol. 21, no.1, p. 578 [1-12] (2021)
BMC Cancer
BMC cancer, Vol. 21, no.1, p. 578 [1-12] (2021)
BackgroundThe viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. The safety of systemic anti-cancer therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b52246cc3435a528b1aacdaf46d72ecf
https://doaj.org/article/95bcb44e832f4789979432b41c90aaa4
https://doaj.org/article/95bcb44e832f4789979432b41c90aaa4
Autor:
Stéphanie Laurent, Marc Peeters, Ivan Borbath, Thierry Delaunoit, J.-L. Van Laethem, Marianne Paesmans, Anne Demols, J.-C. Goemine, Raphaël Maréchal, M. Van den Eynde, Ghislain Houbiers, Stéphane Holbrechts
Publikováno v:
Annals of oncology, Vol. 31, no.9, p. 1169-1177 (2020)
Annals of oncology, 2020 Sep (31(9
Annals of oncology
Annals of oncology, 2020 Sep (31(9
Annals of oncology
Background: There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c65f3d06c1d9e21a4b4ad199e710f641
https://doi.org/10.1016/j.annonc.2020.05.018
https://doi.org/10.1016/j.annonc.2020.05.018
Autor:
F.M. Esposito, J. Lee, S.Y. Rha, K.D. Penkov, A. Moisseev, M. Van Den Eynde, H. Prenen, M. Díez García, M. Gumus, T. Sagawa, M. Nechaeva, T. Kajiwara, H. Harputluoglu, L. Charbonnier, S. Bensfia, N. Yang, D-Y. Oh
Publikováno v:
Annals of Oncology, Vol. 33, no.7, p. 1124 (2022)
Background Tusamitamab ravtansine (tusa; SAR408701), an anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) antibody conjugated to the potent cytotoxic antitubulin DM4, showed promising antitumor activity and was well tolerated i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677730639d60a19a237e4d5cd58de896
https://hdl.handle.net/2078.1/273058
https://hdl.handle.net/2078.1/273058
Autor:
Karel Geboes, Gabriel Liberale, Javier Carrasco, M. Van den Eynde, Giacomo Bregni, Chiara Senti, Amélie Deleporte, Yeter Gokburun, P. Demetter, Alain Hendlisz, E. Acedo Reina, Monika Peeters, Francesco Sclafani, A. Veron, Luigi Moretti, Philippe Vergauwe, Paraskevas Gkolfakis, Marc Buyse, J-L. van Laethem
Publikováno v:
Annals of Oncology, Vol. 32, no.5, p. S579 (2021)
Background Despite recent improvements, management of locally advanced rectal cancer (LARC) remains challenging, and many patients (pts) still experience recurrence. In preclinical models, combining Rego with an anti-PD-1 inhibitor led to superior tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::034319297ff351dad8627c99bf332eca
https://hdl.handle.net/2078.1/273074
https://hdl.handle.net/2078.1/273074
Autor:
Kyoko Kato, W Yu, E. Van Cutsem, S.-B. Kim, M. Van den Eynde, A Tao, F. El Hajbi, S D'Alonzo, Igor I. Rybkin, Peter C. Thuss-Patience, Jaffer A. Ajani, David Cunningham, Maria Alsina, Liang Shen, G.V. Scagliotti
Publikováno v:
Annals of Oncology, Vol. 32, no.5, p. S225 (2021)
Background The global Phase 3 study RATIONALE 302 (NCT03430843) evaluated the efficacy and safety of second-line tislelizumab, an anti-PD-1 antibody, in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). Here, we report d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3220a8acdfa9a0773ac7403d1da5d839
https://hdl.handle.net/2078.1/273082
https://hdl.handle.net/2078.1/273082
Autor:
C. Van Marcke, N. Honoré, A. Van Der Elst, S. Beyaert, F. Derouane, C. Dumont, F. Aboubakar Nana, J. F. Baurain, I. Borbath, P. Collard, F. Cornélis, A. De Cuyper, F. P. Duhoux, B. Filleul, R. Galot, M. Gizzi, F. Mazzeo, T. Pieters, E. Seront, I. Sinapi, M. Van Den Eynde, N. Whenham, J. C. Yombi, A. Scohy, A. Van Maanen, J. P. Machiels
Additional file 1: Table S1. Characteristics of patients who had SARS-CoV-2 RT-PCR. Table S2. Characteristics of patients diagnosed by SARS-CoV-2 serology (SARS-CoV-2 RT-PCR not performed or negative). Table S3. Adverse events with systemic therapy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20714542e956f6b25b5470f879175dcf
Autor:
Julien Taieb, E. Elez Fernandez, Axel Grothey, E. Carriere Roussel, M. Van den Eynde, A. Ruiz Casado, Takayuki Yoshino, Z. Issiakhem, J. Vedovato, B. Jean, Evaristo Maiello, Thierry André, T. Kato, E. Van Cutsem, C. Cahuzac, Paul Ross, Janet Graham, Rona Yaeger, J. Ruffinelli, R. Vera, J. Tabernero
Publikováno v:
Annals of Oncology, Vol. 31, no.3, p. S242-S243 (2020)
Background BRAFV600E mutations are identified in 8-15% of metastatic colorectal cancer (mCRC) patients and confer a poor prognosis. In patients with BRAFV600E-mutant mCRC, the combination of encorafenib (ENCO) + cetuximab (CETUX) ± binimetinib (BINI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9692af7497c2a84c8b436e1668999ff9
https://hdl.handle.net/2078.1/273102
https://hdl.handle.net/2078.1/273102
Autor:
Fabienne Hermitte, Bernhard Mlecnik, Alessandro Lugli, Carlo Bifulco, Franck Pages, Eva Zavadova, Francesco M. Marincola, Pamela S. Ohashi, M. Van den Eynde, F. Marliot, P.A. Ascierto, Jérôme Galon, Bernard A. Fox, A. Hartmann, Yutaka Kawakami, Youhan Wang, Toshihiko Torigoe, Michael H.A. Roehrl, Iris D. Nagtegaal, P. Patel
Publikováno v:
Annals of Oncology, Vol. 31, no.3, p. 238 (2020)
Background The present study was performed to evaluate the predictive capacity of the TNM-Immune (TNM-I) classification staging system vs. the 8th edition of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1640e04530d526d73a6d7d0d98f518d
https://hdl.handle.net/2078.1/273098
https://hdl.handle.net/2078.1/273098